A Phase II Trial Of ZD1839 (Iressa) In Metastatic Neuroendocrine Tumors
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2013
At a glance
- Drugs Gefitinib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 05 May 2011 Status changed from active, no longer recruiting to completed.
- 19 Jul 2007 Status change
- 04 Jun 2007 Status changed from suspended to in progress.